Recognizing rheumatoid arthritis: Oncoprotein survivin opens new possibilities: A population-based case-control study

Medicine (United States)

Volumn 94, Issue 4, 2015, Pages

  Chun Lai, Too ^a,b   Murad, Shahnaz ^a   Erlandsson, Malin C ^c   Hussein, Heselynn ^d   Sulaiman, Wahinuddin ^e   Dhaliwal, Jasbir S ^a   Bokarewa, Maria I ^c  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d PUTRAJAYA HOSPITAL   (Malaysia)

^e Hospital Raja Permaisuri Bainun   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; HLA DRB1 ANTIGEN; SURVIVIN; AUTOANTIBODY; BIOLOGICAL MARKER; BIRC5 PROTEIN, HUMAN; CYCLOPEPTIDE; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ALLELE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MIDDLE AGED; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; PREDICTIVE VALUE;

ALLELES; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EPITOPES; FEMALE; HLA-DRB1 CHAINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS;

EID: 84938072380     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000468     Document Type: Article

References (38)

1. Eriksson JK, Neovius M, Ernestam S., et al. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res (Hoboken). 2013; 65:870-878.
2. Richman NC, Yazdany J, Graf J., et al. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore). 2013; 92:92-97.
3. See LC, Kuo CF, Chou I.J., et al. Sex- and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study. Semin Arthritis Rheum. 2013; 43:381-386.
4. MacGregor AJ, Snieder H, Rigby A.S., et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000; 43:30-37.
5. Lin JP, Cash JM, Doyle S.Z., et al. Familial clustering of rheumatoid arthritis with other autoimmune diseases. Hum Genet. 1998; 103:475-482.
6. Deighton CM, Walker DJ, Griffiths I.D., et al. The contribution of HLA to rheumatoid arthritis. Clin Genet. 1989; 36:178-182.
7. Lundstrom E, Kallberg H, Smolnikova M., et al. Opposing effects of HLA-DRB1∗ 13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis and rheumatism. 2009; 60:924-930.
8. Mackie SL, Taylor JC, Martin S.G., et al. A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. Genes Immun. 2012; 13:120-128.
9. van der Helm-van Mil AH, Huizinga TW, de Vries RR, et al. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum. 2007; 56:1728-1735.
10. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987; 30:1205-1213.
11. Mattey DL, Dawes PT, Gonzalez-Gay MA, et al. HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development of rheumatoid arthritis. J Rheumatol. 2001; 28:232-239.
12. Raychaudhuri S, Sandor C, Stahl E.A., et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012; 44:291-296.
13. van der Helm-van Mil AH, Huizinga TW, Schreuder GM, et al. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis Rheum. 2005; 52:2637-2644.
14. van der Woude D, Lie BA, Lundstrom E, et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1∗1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 2010; 62:1236-1245.
15. Zanelli E, Huizinga TW, Guerne P.A., et al. An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Immunogenetics. 1998; 48:394-401.
16. Hill JA, Bell DA, Brintnell W, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 2008; 205:967-979.
17. Scally SW, Petersen J, Law S.C., et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med. 2013; 210:2569-2582.
18. Bhayani HR, Hedrick SM. The role of polymorphic amino acids of the MHC molecule in the selection of the T cell repertoire. J Immunol. 1991; 146:1093-1098.
19. Klareskog L, Ronnelid J, Lundberg K., et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008; 26:651-675.
20. Law SC, Street S, Yu C.H., et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther. 2012; 14:R118.
21. Bang SY, Lee KH, Cho S.K., et al. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum. 2010; 62:369-377.
22. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3:917-921.
23. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008; 8:61-70.
24. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006; 5:1087-1098.
25. Singh P, Hoggatt J, Hu P., et al. Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells. Blood. 2012; 119:1671-1682.
26. Andersson SE, Svensson MN, Erlandsson M.C., et al. Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One. 2012; 7:e47668.
27. Okada H, Bakal C, Shahinian A., et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med. 2004; 199:399-410.
28. Xing Z, Conway EM, Kang C, et al. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. 2004; 199:69-80.
29. Song J, So T, Croft M. Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol. 2008; 180:7240-7248.
30. Lei F, Song J, Haque R., et al. Transgenic expression of survivin compensates for OX40-deficiency in driving Th2 development and allergic inflammation. Eur J Immunol. 2013; 43:1914-1924.
31. Bokarewa M, Brink M, Erlandsson M., et al. Survivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study. Arthritis Res Ther. 2014; 16:R45.
32. Svensson B, Hafstrom I, Forslind K., et al. Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med. 2010; 42:45-54.
33. Isgren A, Forslind K, Erlandsson M., et al. High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2012; 41:652-657.
34. Arnett FC, Edworthy SM, Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315-324.
35. Too CL, Yahya A, Murad S., et al. Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther. 2012; 14:R89.
36. Chun-Lai T, Padyukov L, Dhaliwal J.S., et al. Shared epitope alleles remain a risk factor for anti-citrullinated proteins antibody (ACPA)-positive rheumatoid arthritis in three Asian ethnic groups. PLoS One. 2011; 6:e21069.
37. Klareskog L, Stolt P, Lundberg K., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006; 54:38-46.
38. Svensson B, Hafstrom I, Erlandsson M.C., et al. Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther. 2014; 16:R12.